Biopolym. Cell. 2012; 28(6):413-423.
Interaction of actin with plasminogen/plasmin system: mechanisms and physiological role
1Tykhomyrov A. A.
  1. Palladin Institute of Biochemistry, NAS of Ukraine
    9, Leontovycha Str., Kyiv, Ukraine, 01601


In the present review, we have summarized and analyzed the literature data concerning cooperation between multifunctional proteins, the components of plasminogen/plasmin system and actin. The mechanisms underlying intermolecular interactions and the role of plasminogen kringle domains in protein-protein recognition are reviewed. A particular attention is paid to extracellular actin that serves as a surface protein of plasma membrane in various cells. A putative role of surface actin as the universal «non-hemostatic» center of plasminogen activation is discussed. The exposition of cytoskeletal actin on the outer surface of cellular membrane is thought to be a phenomenon, which is involved in both normal cell functioning and development of pathologies. In particular, the mechanism of plasminogen fragmentation on the surface of cancer cells mediated by actin, which results in generation of endogenous suppressors of tumor growth and metastazing (angiostatins), is described. It has been acknowledged that the plasminogen/plasmin system in concert with surface actin regulates releasing biologically active substances, e. g. catecholamines. The comprehensive assessment of plasminogen/plasmin system and surface actin exposition is proposed to be a criterion of functional status of cells and can be used as a diagnostic parameter at various pathologies.
Keywords: multifunctional proteins, plasminogen/plasmin system, actin


[1] Smalheiser N. R. 1996 Proteins in unexpected locations Mol. Biol. Cell 7, N 7:1003–1014.
[2] Reisler E., Egelman E. H. 2007 Actin structure and function: what we still do not understand J. Biol. Chem 282, N 50:36133–36137.
[3] Owen M. J., Auger J., Barber B. H., Edwards A. J., Walsh F. S., Crumpton M. J. 1978 Actin may be present on the lymphocyte surface Proc. Natl Acad. Sci. USA 75, N 9:4484–4488.
[4] Por S. B., Cooley M. A., Breit S. N., Penny R., French P. W. 1991 Antibodies to tubulin and actin bind to the surface of a human monocytic cell line, U937 J. Histochem. Cytochem 39, N 7:981–985.
[5] Liu D. Y., Clarke G. N., Baker H. W. 2005 Exposure of actin on the surface of the human sperm head during in vitro culture relates to sperm morphology, capacitation and zona binding Hum. Reprod 20, N 4:999–1005.
[6] Moroianu J., Fett J. W., Riordan J. F., Vallee B. L. 1993 Actin is a surface component of calf pulmonary artery endothelial cells in culture Proc. Natl Acad. Sci. USA 90, N 9:3815–3819.
[7] Wang H., Doll J. A., Jiang K., Cundiff D. L., Czarnecki J. S., Wilson M., Ridge K. M., Soff G. A. 2006 Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis Cancer Res 66, N 14:7211–7215.
[8] Lugovskoy E. V. 2003 Molecular mechanisms of fibrin formation and fibrinolysis Kiev: Naukova Dumka, 224 p.
[9] Zhernossekov D. D., Yusova E. I., Grinenko T. V. 2012 Role of plasminogen/plasmin in functional activity of blood cells Ukr. Biokhim. Zh 84, N 4:5–19.
[10] Roka-Moya Y. M., Zhernossekov D. D., Grinenko T. V. 2012 Plasminogen/plasmin influence on platelet aggregation Biopolym. Cell 28, N 5:352–356.
[11] Doll J. A., Soff G. A. 2005 Angiostatin Cancer Treat. Res 126:175–204.
[12] Klys' Y. G., Zajtseva N. V., Kizim A. I., Verevka S. V. 2010 Proteolytic derivates of plasminogen as a factor in malignancy development Oncology 12, N 1:17–21.
[13] Dudani A. K., Ganz P. R. 1996 Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a) Br. J. Haematol 95, N 1:168–178.
[14] George J. N., Lyons R. M., Morgan R. K. 1980 Membrane changes associated with platelet activation. Exposure of actin on the platelet surface after thrombin-induced secretion J. Clin. Invest 66, N 1:1–9.
[15] Giometti C. S., Willard K. E., Anderson N. L. 1982 Cytoskeletal proteins from human skin fibroblasts, peripheral blood leukocytes, and a lymphoblastoid cell line compared by two-dimensional gel electrophoresis Clin. Chem 28, N 4, pt 2:955–961.
[16] Le Beux Y. J., Willemot J. 1978 Actinand myosin-like filaments in rat brain pericytes Anat. Rec 190, N 4:811–826.
[17] Accinni L., Natali P. G., Silvestrini M., De Martino C. 1983 Actin in the extracellular matrix of smooth muscle cells. An immunoelectron microscopic study Connect. Tissue Res 11, N 1:69–78.
[18] Miles L. A., Andronicos N. M., Baik N., Parmer R. J. 2006 Cell-surface actin binds plasminogen and modulates neurotransmitter release from catecholaminergic cells J. Neurosci 26, N 50:13017–13024.
[19] Dominguez R., Holmes K. C. 2011 Actin structure and function Annu. Rev. Biophys 40:169–186.
[20] Khaitlina S. Yu. 2007 Mechanisms of spatial segregation of actin isoforms Tsitologiya 49, N 5:345–354.
[21] Mazzocci C., Benos D. J., Smith P. R. 2006 Interaction of epithelial ion channels with the actin-based cytoskeleton Am. J. Physiol. Renal Physiol 291, N 6 F1113–1122.
[22] de Lanerolle P., Cole A. B. 2002 Cytoskeletal proteins and gene regulation: form, function, and signal transduction in the nucleus Sci. STKE 139 pe30.
[23] Percipalle P., Visa N. 2006 Molecular functions of nuclear actin in transcription J. Cell Biol 172, N 7:967–971.
[24] Dillon C., Goda Y. 2005 The actin cytoskeleton: integrating form and function at the synapse Annu. Rev. Neurosci 28:25–55.
[25] Su Y., Kondrikov D., Block E. R. 2005 Cytoskeletal regulation of nitric oxide synthase Cell Biochem. Biophys 43, N 3:439–449.
[26] Yamaguchi H., Condeelis J. 2007 Regulation of the actin cytoskeleton in cancer cell migration and invasion Biochim. Biophys. Acta 1773, N 5:642–652.
[27] Cossart P., Sansonetti P. J. 2004 Bacterial invasion: the paradigm of enteroinvasive pathogens Science 304, N 5668:242–248.
[28] Bachvaroff R. J., Miller F., Rapaport F. T. 1980 Appearance of cytoskeletal components on the surface of leukemia cells and of lymphocytes transformed by mitogens and Epstein-Barr virus Proc. Natl Acad. Sci. USA 77, N 8:4979–4983.
[29] Forlemu N. Y., Njabon E. N., Carlson K. L., Schmidt E. S., Waingeh V. F., Thomasson K. A. 2011 Ionic strength dependence of F-actin and glycolytic enzyme associations: a Brownian dynamics simulations approach Proteins 79, N 10:2813–2827.
[30] Novokhatny V. V., Matsuka Y. V. 1989 Plasminogen: structure and physico-chemical properties Biochemistry of Animals and Human N 13:36–45.
[31] Ponting C. P., Marshall J. M., Cederholm-Williams S. A. 1992 Plasminogen: a structural review Blood Coagul. Fibrinolysis 3, N 5:605–614.
[32] Fredenburgh J. C., Nesheim M. E. 1992 Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro J. Biol. Chem 267, N 36:26150– 26156.
[33] Hrynenko T. V., Iusova O. I., Zadorozhna M. B., Makohonenko Ie. M. 2002 Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin Ukr. Biokhim. Zh 74, N 6:83–90.
[34] Castellino F. J., McCance S. G. 1997 The kringle domains of human plasminogen Ciba Found. Symp 212:46–60.
[35] Zhang L., Seiffert D., Fowler B. J., Jenkins G. R., Thinnes T. C., Loskutoff D. J., Parmer R. J., Miles L. A. 2002 Plasminogen has a broad extrahepatic distribution Thromb. Haemost 87, N 3:493–501.
[36] Plow E. F., Herren T., Redlitz A., Miles L. A., Hoover-Plow J. L. 1995 The cell biology of the plasminogen system FASEB J 9, N 10:939–945.
[37] Miles L. A., Hawley S. B., Baik N., Andronicos N. M., Castellino F. J., Parmer R. J. 2005 Plasminogen receptors: the sine qua non of cell surface plasminogen activation Front. Biosci 10:1754– 1762.
[38] Herren T., Swaisgood C., Plow E. F. 2003 Regulation of plasminogen receptors Front. Biosci 8 d1-8.
[39] Ranson M., Andronicos N. M. 2003 Plasminogen binding and cancer: promises and pitfalls Front. Biosci 8 s294–304.
[40] Farris S. D., Hu J. H., Krishnan R., Emery I., Chu T., Du L., Kremen M., Dichek H. L., Gold E., Ramsey S. A., Dichek D. A. 2011 Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins J. Biol. Chem 286, N 25:22665–22677.
[41] Szekanecz Z., Besenyei T., Paragh G., Koch A. E. 2009 Angiogenesis in rheumatoid arthritis Autoimmunity 42, N 7:563–573.
[42] Sodha N. R., Clements R. T., Boodhwani M., Xu S. H., Laham R. J., Bianchi C., Sellke F. W. 2009 Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation Am. J. Physiol. Heart Circ. Physiol 296, N 2 H428–434.
[43] Vagnucci A. H. Jr., Li W. W. 2003 Alzheimer's disease and angiogenesis Lancet 361, N 9357:605–608.
[44] Syrovets T., Lunov O., Simmet T. 2012 Plasmin as a proinflammatory cell activator J. Leukoc. Biol 92, N 3:509–519.
[45] Tarui T., Majumdar M., Miles L. A., Ruf W., Takada Y. 2002 Plasmininduced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin J. Biol. Chem 277, N 37:33564–33570.
[46] Sharma M., Ownbey R. T., Sharma M. C. 2010 Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation Exp. Mol. Pathol 88, N 2:278–286.
[47] Wang H., Schultz R., Hong J., Cundiff D. L., Jiang K., Soff G. A. 2004 Cell surface-dependent generation of angiostatin4.5 Cancer Res 64, N 1:162–168.
[48] Wahl M. L., Moser T. L., Pizzo S. V. 2004 Angiostatin and anti-angiogenic therapy in human disease Recent Prog. Horm. Res 59:73–104.
[49] Chavakis T., Athanasopoulos A., Rhee J. S., Orlova V., SchmidtWoll T., Bierhaus A., May A. E., Celik I., Nawroth P. P., Preissner K. T. 2005 Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment Blood 105, N 3:1036–1043.
[50] Mejean C., Roustan C., Benyamin Y. 1987 Anti-actin antibodies. Detection and quantitation of total and skeletal muscle actin in human plasma using a competitive ELISA J. Immunol. Methods 99, N 1:129–135.
[51] Rubenstein P., Ruppert T., Sandra A. 1982 Selective isoactin release from cultured embryonic skeletal muscle cells J. Cell Biol 92, N 1:164–169.
[52] Janmey P. A., Lind S. E. 1987 Capacity of human serum to depolymerize actin filaments Blood 70, N 2:524–530.
[53] Lind S. E., Smith C. J. 1991 Actin accelerates plasmin generation by tissue plasminogen activator J. Biol. Chem 266, N 26:17673–17678.
[54] Lind S. E., Smith C. J. 1991 Actin is a noncompetitive plasmin inhibitor J. Biol. Chem 266, N 8:5273–5278.
[55] Huber D., Cramer E. M., Kaufmann J. E., Meda P., Masse J. M., Kruithof E. K., Vischer U. M. 2002 Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo Blood 99, N 10:3637–3645.
[56] Sidenius N., Blasi F. 2003 The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy Cancer Metastasis Rev 22, N 2–3:205–222.
[57] Foekens J. A., Peters H. A., Look M. P., Portengen H., Schmitt M., Kramer M. D., Brunner N., Janicke F., Meijer-van Gelder M. E., Henzen-Logmans S. C., van Putten W. L., Klijn J. G. 2000 The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients Cancer Res 60, N 3:636–643.
[58] Stillfried G. E., Saunders D. N., Ranson M. 2007 Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity Breast Cancer Res 9, N 1 R14.
[59] Andronicos N. M., Ranson M. 2001 The topology of plasminogen binding and activation on the surface of human breast cancer cells Br. J. Cancer 85, N 6:909–916.
[60] Stack M. S., Gately S., Bafetti L. M., Enghild J. J., Soff G. A. 1999 Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation Biochem. J 340, pt 1:77–84.
[61] McColl B. K., Baldwin M. E., Roufail S., Freeman C., Moritz R. L., Simpson R. J., Alitalo K., Stacker S. A., Achen M. G. 2003 Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D J. Exp. Med 198, N 6:863–868.
[62] Schaller J., Gerber S. S. 2011 The plasmin-antiplasmin system: structural and functional aspects Cell Mol. Life Sci 68, N 5:785–801.
[63] Chang Y., Mochalkin I., McCance S. G., Cheng B., Tulinsky A., Castellino F. J. 1998 Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen Biochemistry 37, N 10:3258–3271.
[64] Human physiology: handbook 2003 Ed. V. M. Pokrovsky, G. F. Koryt'ko Moscow: Medicine, 656 p.
[65] Feldman S. A., Eiden L. E. 2003 The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia Endocr. Pathol 14, N 1:3–23.
[66] Metz-Boutigue M. H., Garcia-Sablone P., Hogue-Angeletti R., Aunis D. 1993 Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites Eur. J. Biochem 217, N 1:247–257.
[67] Parmer R. J., Mahata M., Gong Y., Mahata S. K., Jiang Q., O'Connor D. T., Xi X. P., Miles L. A. 2000 Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion J. Clin. Invest 106, N 7:907–915.
[68] Colombo B., Longhi R., Marinzi C., Magni F., Cattaneo A., Yoo S. H., Curnis F., Corti A. 2002 Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion J. Biol. Chem 277, N 48:45911– 45919.
[69] Salles F. J., Strickland S. 2002 Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus J. Neurosci 22, N 6:2125–2134.
[70] O'Rourke J., Jiang X., Hao Z., Cone R. E., Hand A. R. 2005 Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature J. Neurosci. Res 79, N 6:727–733.